Eli Lilly’s weight loss drug, tirzepatide, showed substantial potential in a large Phase 3 study, the results of which were reported on April 28th. If tirzepatide gets approved, it could become a blockbuster. But, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles.
Subscribe to:
Post Comments (Atom)
< + > Beyond the Science by Gary Zammit – Life Sciences Today Podcast Episode 46
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Gary Zammit, PhD,...
No comments:
Post a Comment